利妥昔单抗联合GDP方案治疗复发难治性弥漫大B细胞淋巴瘤的疗效观察

Observation of the curative effect of rituximab combined with GDP regimen in the treatment of recurrent and refractory diffuse large B-cell lymphoma

目的：观察利妥昔单抗联合GDP方案治疗复发难治性弥漫大B细胞淋巴瘤（DLBCL）的疗效和不良反应。方法：2009—01—2013-12在我院住院的复发难治性DLBCL患者28例，采用利妥昔单抗联合GDP方案化疗（利妥昔单抗375mg／m^2d0，吉西他滨1000mg／m^2dl、8，顺铂25mg／m^2d1～3，地塞米松40mg／dd1～4），21d为一个疗程。完成2个疗程后评价疗效及不良反应。结果：随访9～58个月，28例患者中13例获得完全缓解，9例获得部分缓解，1例疾病稳定，5例疾病进展，总有效率为78．6％；常见的不良反应为骨髓抑制和胃肠道反应。结论：利妥昔单抗联合GDP方案是治疗复发难治性DLBCL一个安全有效的挽救方案。

Objective：To explore the effect of rituximab combined with GDP regimen in the treatment of recurrent and refractory diffuse large P-cell lymphoma （DI,BCL） and adverse effect. Method： A total of 28 cases of refractory and relapsed DLBCL from January 2009 to December 2013 in our hospital,we used the combination of rituximab and GDP chemotherapy （rituximab 375 mg/m2 d0, gemcitabine 1 000 mg/m2 d1, 8, cisplatin 25 mg/m2 d1-3,dexamethasone 40 mg/d d1-4）, 21 days for a course of treatment. Curative effect and adverse reaction evaluation completed after two courses. Result： Followed up for 9-58 months, 13 cases achieved complete remission,9 cases achieved partial remission, 1 patients with stable disease,5 patients with disease progression,the total efficiency was 78.6%. Common adverse reactions were myelosuppression and gastrointestinal tract reaction. Conclusion：Rituximab combined with GDP is a safe and effective saving scheme for relapsed refractory DLBCL.